TAVEXIA LIFECARE (BSE: TAVEXIA) is loss-making over the last 12 months, losing ₹0.63 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹1.16. Sales grew 144% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹44 Cr, ranked 26th of 34 Household & Personal Products companies by market cap; the shares rose 48% over the past year.
- ₹1.16
- ₹1.17
- ₹1.16
- ₹1.17
- 2.4 L
Health check
- ReturnsAhead
+48.1% over a year, better than 6 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +144.2%, profit −27.4% a year over 3 years, but loss-making now.
- ProfitabilityWeak
ROCE 0.5% vs peer median 30.8%.
- Balance sheetStretched
Debt 0.08× equity, interest covered 5.3×, Piotroski 3 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹44 Cr
- Small cap
- P/E
- 23.2
- Industry 28.7
- Price to book
- 1.03
- Peers 24.59
- Dividend yield
- 0.00%
- ROE
- 0.6%
- Peers 27.3%
- ROCE
- 0.5%
- Peers 30.8%
- Debt to equity
- 0.08
- Debt ₹3.51 Cr
- EPS (TTM)
- ₹0.05
- OPM (TTM)
- −19.4%
- Net margin −2.0%
- Sales growth
- −47.0%
- Latest quarter vs a year ago
- Profit growth
- −124.6%
- Latest quarter vs a year ago
- Price to sales
- 1.40
- EV/EBITDA −4.7
Strengths and risks
Strengths
- Practically debt-free.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at 0.6%.
- Quarterly profit down 124.6% on a year ago.
- Quarterly sales down 47.0% on a year ago.
- Interest coverage of only −131.1×.
About TAVEXIA LIFECARE
Tavexia Lifecare Limited operates a trading and distribution business and is developing a vertically integrated pharmaceutical and lifecare platform serving India and international markets. The company offers pharmaceutical contract development and manufacturing services for oral solids, oral liquids, and external preparations; sources, markets, and distributes active pharmaceutical ingredients to formulators in India and overseas; and exports finished…
- Headquarters
- Mumbai
- Employees
- 11
- Sector
- Consumer Defensive
- ISIN
- INE280E01038
- Website
- tavexia.com
Price range
- Avg volume (3M)
- 11.3 L
- 1-year return
- plus 48.1%
- From 52-week high
- minus 7.2%
Peers · Household & Personal Products
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HINDUNILVRHindustan Unilever | 1,998.40 | plus 0.83% | 4,69,542 | 44.4 | 9.62 | 22.2% | 21.6% | 23.1% | 2.3% | 14.1% | 2.05% | minus 19.0% |
| MARICOMarico | 897.75 | plus 1.13% | 1,16,527 | 57.7 | 24.59 | 38.8% | 44.9% | 17.4% | 11.8% | 10.6% | 0.45% | plus 23.8% |
| GODREJCPGodrej Consumer Products | 851.00 | minus 1.36% | 87,097 | 44.0 | 6.90 | 21.3% | 16.0% | 20.2% | 4.6% | 3.0% | 2.35% | minus 25.8% |
| DABURDabur India | 380.35 | minus 1.21% | 67,477 | 33.4 | 5.87 | 20.8% | 17.2% | 18.5% | 4.5% | 3.5% | 2.17% | minus 25.5% |
| COLPALColgate Palmolive (India) | 1,679.00 | minus 0.53% | 45,666 | 33.5 | 28.23 | 107.4% | 85.1% | 30.1% | 4.9% | 8.2% | 2.86% | minus 23.0% |
| CUPIDCupid | 338.90 | minus 0.69% | 45,571 | 338.9 | 100.95 | 30.8% | 27.3% | 35.4% | 31.2% | 50.8% | 0.00% | plus 607.7% |
| GILLETTEGillette India | 7,406.50 | minus 0.17% | 24,134 | 36.1 | 25.50 | 84.6% | 68.2% | 30.2% | – | – | 2.43% | minus 15.3% |
| TAVEXIATAVEXIA LIFECARE | 1.16 | minus 0.85% | 44 | 23.2 | 1.03 | 0.5% | 0.6% | −19.4% | 144.2% | −27.4% | 0.00% | plus 48.1% |
| Median of 7 peers | – | −0.53% | 67,477 | 44.0 | 24.59 | 30.8% | 27.3% | 23.1% | 4.7% | 9.4% | 2.17% | −19.0% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 1.2 | 16.8 | 5.7 | 8.5 | 0.6 | |
| 0.4 | 15.7 | 6.2 | 15 | 0.9 | |
| 0.8 | 1.2 | −0.5 | −6.5 | −0.2 | |
| 64.2% | 6.9% | −9.5% | −76.7% | −36.4% | |
| 0 | 0 | 0 | 5.8 | 0.1 | |
| 0 | 0 | 0 | 0 | 0.1 | |
| 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | |
| 0.7 | 1.1 | −0.7 | −0.9 | −0.3 | |
| 5.8% | 25.7% | 1.3% | 18.8% | 48.4% | |
| 0.7 | 0.7 | −0.5 | −0.4 | −0.2 | |
| 0.03 | 0.09 | -0.02 | -0.02 | -0.00 |
Profit & loss
- Sales CAGR 3Y
- +144.2%
- Profit CAGR 3Y
- −27.4%
- EPS CAGR 3Y
- −34.5%
- ROE
- 0.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 2.2 | 3.6 | 5.3 | 32.2 | |
| – | +60.6% | +48.1% | +512.7% | |
| 1.2 | 1.6 | 2 | 37.3 | |
| 1 | 1.9 | 3.3 | −5 | |
| 45.8% | 54.3% | 61.9% | −15.6% | |
| 0 | 0 | 0.4 | 5.5 | |
| 0 | 0 | 0 | 0 | |
| 0.2 | 0.4 | 0.4 | 0.6 | |
| – | – | 0 | 0.3 | |
| 0.8 | 1.5 | 3.2 | 0.2 | |
| 27.4% | 22.3% | 21.9% | −27.2% | |
| 0.6 | 1.2 | 2.5 | 0.2 | |
| – | +115.1% | +109.1% | minus 91.5% | |
| 0.04 | 0.05 | 0.11 | 0.01 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 8.1 | 12.1 | 19.3 | 38.4 | |
| 7.4 | 10.1 | 4.7 | 4.9 | |
| 0.2 | 0.2 | 0.5 | 3.5 | |
| 0.6 | 0.9 | 2.1 | 64.6 | |
| 16.4 | 23.3 | 26.6 | 111 | |
| 1.2 | 1.1 | 1.1 | 3.8 | |
| 8.1 | 10.9 | 10.9 | 11.4 | |
| 3.1 | 0 | 0 | 1.4 | |
| 3.9 | 11.2 | 14.5 | 94.7 | |
| 16.4 | 23.3 | 26.6 | 111 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −1.5 | −2.8 | 0.1 | −14.3 | |
| −9.7 | −2.8 | −0.5 | −3.6 | |
| 11.2 | 5.5 | 0.4 | 19.3 | |
| 0 | −0 | −0 | 1.4 | |
| −1.6 | −0 | −0.5 | −3.2 | |
| −3 | −2.8 | −0.4 | −17.5 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.